Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from ConvaTec ( (GB:CTEC) ) is now available.
ConvaTec Group PLC has executed a share buyback transaction as part of its previously announced $300 million program. The company purchased 237,996 ordinary shares at a volume-weighted average price of 235.49 pence per share, which will be held in treasury. This move is part of ConvaTec’s strategy to manage its capital structure and return value to shareholders, potentially impacting its market positioning and shareholder interests.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.25 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC is a global medical products and technologies company focused on therapies for the management of chronic conditions, with primary products in wound care, ostomy care, continence and critical care, and infusion devices.
Average Trading Volume: 9,084,815
Technical Sentiment Signal: Hold
Current Market Cap: £4.62B
Find detailed analytics on CTEC stock on TipRanks’ Stock Analysis page.